Health Condition 1: G63- Polyneuropathy in diseases classified elsewhere
Conditions
Interventions
Intervention1: PREGABALIN: Start with per oral tab Pregabalin 50 mg per day, In case of sub-optimal response, increase the dose by 50 mg, every week till 6 weeks, reaching a maximum dose upto 300 mg.
Sponsors
Non sponsored
Eligibility
Inclusion criteria
Inclusion criteria: Both male and female cancer patients, ages 18 and older, who develop peripheral sensory neuropathy after chemotherapy infusion and are willing to participate in the study, will be included.
Exclusion criteria
Exclusion criteria: Subjects less than 18 years of age, history of any comorbidities like chronic kidney disease, chronic liver disease or if there is any history of drug addiction or substance abuse, will be excluded. Those who fulfil the inclusion criteria but not giving consent to participate in the study will also excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure will be the mean percentage change in NCI CTCAE CIPN grading and VAS pain score, both at 2 weeks and 6 weeks of study.Timepoint: 2 weeks and 6 weeks from the starting point of study. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome measure will be calculated by mean percentage change in quality of life score between two groups, which is EORTC QLQ CIPN 20 score, at 6 weeks from the starting point of studyTimepoint: 6 weeks from the study initiation point. | — |
Countries
India
Contacts
Public ContactSushmita Ranga
Sir ganga ram hospital, New Delhi
Outcome results
None listed